A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Bavituximab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 11 Jul 2013 The company have no further plans for studies in pancreatic cancer at this time, according to the fiscal year report issued by Peregrine Pharmaceuticals in July 2013.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History